The Relapsed or Refractory Diffuse Large B-cell Lymphoma Market presents a challenging frontier in oncology, characterized by the recurrence or resistance of this aggressive form of non-Hodgkin lymphoma to standard treatments. Diffuse large B-cell lymphoma (DLBCL) accounts for a significant proportion of lymphoma cases globally, and despite advancements in treatment, a subset of patients...
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
urdu